202 related articles for article (PubMed ID: 30371038)
1. The Management of Permanent Primary Hypoparathyroidism in Children and Adolescents: A Complex Task.
De Sanctis V; Soliman AT; Di Maio S; Kattamis C
Pediatr Endocrinol Rev; 2018 Sep; 16(1):194-202. PubMed ID: 30371038
[TBL] [Abstract][Full Text] [Related]
2. Management of hypoparathyroidism: a Position Statement of the Expert Group of the Polish Society of Endocrinology.
Misiorowski W; Dedecjus M; Konstantynowicz J; Zygmunt A; Kos-Kudła B; Lewiński A; Ruchała M; Zgliczyński W
Endokrynol Pol; 2023; 74(5):447-467. PubMed ID: 37902011
[TBL] [Abstract][Full Text] [Related]
3. Evaluation and Management of Hypoparathyroidism Summary Statement and Guidelines from the Second International Workshop.
Khan AA; Bilezikian JP; Brandi ML; Clarke BL; Gittoes NJ; Pasieka JL; Rejnmark L; Shoback DM; Potts JT; Guyatt GH; Mannstadt M
J Bone Miner Res; 2022 Dec; 37(12):2568-2585. PubMed ID: 36054621
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human parathyroid hormone (1-84) replacement therapy in a child with hypoparathyroidism.
Laurer E; Grünberger J; Naidoo U; Lanzersdorfer R; Wimleitner M; Tischlinger K; Högler W
Bone; 2021 Mar; 144():115834. PubMed ID: 33359892
[TBL] [Abstract][Full Text] [Related]
5. Natpara for the treatment of hypoparathyroidism.
Marcucci G; Della Pepa G; Brandi ML
Expert Opin Biol Ther; 2016 Nov; 16(11):1417-1424. PubMed ID: 27689826
[TBL] [Abstract][Full Text] [Related]
6. Drug safety evaluation of parathyroid hormone for hypocalcemia in patients with hypoparathyroidism.
Marcucci G; Della Pepa G; Brandi ML
Expert Opin Drug Saf; 2017 May; 16(5):617-625. PubMed ID: 28332412
[TBL] [Abstract][Full Text] [Related]
7. American Thyroid Association Statement on Postoperative Hypoparathyroidism: Diagnosis, Prevention, and Management in Adults.
Orloff LA; Wiseman SM; Bernet VJ; Fahey TJ; Shaha AR; Shindo ML; Snyder SK; Stack BC; Sunwoo JB; Wang MB
Thyroid; 2018 Jul; 28(7):830-841. PubMed ID: 29848235
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1-84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study.
Clarke BL; Kay Berg J; Fox J; Cyran JA; Lagast H
Clin Ther; 2014 May; 36(5):722-36. PubMed ID: 24802860
[TBL] [Abstract][Full Text] [Related]
9. PTH(1-84) replacement therapy in hypoparathyroidism: a randomized controlled trial on pharmacokinetic and dynamic effects after 6 months of treatment.
Sikjaer T; Amstrup AK; Rolighed L; Kjaer SG; Mosekilde L; Rejnmark L
J Bone Miner Res; 2013 Oct; 28(10):2232-43. PubMed ID: 23649554
[TBL] [Abstract][Full Text] [Related]
10. Therapy with PTH 1-34 or calcitriol and calcium in diverse etiologies of hypoparathyroidism over 27 years at a single tertiary care center.
Winer KK; Ye S; Ferré EMN; Schmitt MM; Zhang B; Cutler GB; Lionakis MS
Bone; 2021 Aug; 149():115977. PubMed ID: 33932619
[TBL] [Abstract][Full Text] [Related]
11. Five-year Estimated Glomerular Filtration Rate in Patients With Hypoparathyroidism Treated With and Without rhPTH(1-84).
Chen KS; Gosmanova EO; Curhan GC; Ketteler M; Rubin M; Swallow E; Zhao J; Wang J; Sherry N; Krasner A; Bilezikian JP
J Clin Endocrinol Metab; 2020 Oct; 105(10):e3557-65. PubMed ID: 32738041
[TBL] [Abstract][Full Text] [Related]
12. PTH and bone material strength in hypoparathyroidism as measured by impact microindentation.
Starr JR; Tabacco G; Majeed R; Omeragic B; Bandeira L; Rubin MR
Osteoporos Int; 2020 Feb; 31(2):327-333. PubMed ID: 31720712
[TBL] [Abstract][Full Text] [Related]
13. Endocrine Complications of Surgical Treatment of Thyroid Cancer: An Update.
Iglesias P; Díez JJ
Exp Clin Endocrinol Diabetes; 2017 Sep; 125(8):497-505. PubMed ID: 28444664
[TBL] [Abstract][Full Text] [Related]
14. Current treatment of hypoparathyroidism: Theory versus reality waiting guidelines for children and adolescents.
Di Maio S; Soliman AT; De Sanctis V; Kattamis CC
Acta Biomed; 2018 Mar; 89(1):122-131. PubMed ID: 29633734
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular Autonomic Neuropathy as a New Complication of Postsurgical Chronic Hypoparathyroidism.
Tabacco G; Naciu AM; Maggi D; Santonati A; Pedone C; Cesareo R; Bosco D; Gaspa G; Napoli N; Pozzilli P; Manfrini S; Palermo A
J Bone Miner Res; 2019 Mar; 34(3):475-481. PubMed ID: 30395692
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study.
Mannstadt M; Clarke BL; Vokes T; Brandi ML; Ranganath L; Fraser WD; Lakatos P; Bajnok L; Garceau R; Mosekilde L; Lagast H; Shoback D; Bilezikian JP
Lancet Diabetes Endocrinol; 2013 Dec; 1(4):275-83. PubMed ID: 24622413
[TBL] [Abstract][Full Text] [Related]
17. Hypoparathyroidism - disease update and emerging treatments.
Monis EL; Mannstadt M
Ann Endocrinol (Paris); 2015 May; 76(2):84-8. PubMed ID: 25882889
[TBL] [Abstract][Full Text] [Related]
18. Hypoparathyroidism.
Mannstadt M; Bilezikian JP; Thakker RV; Hannan FM; Clarke BL; Rejnmark L; Mitchell DM; Vokes TJ; Winer KK; Shoback DM
Nat Rev Dis Primers; 2017 Aug; 3():17055. PubMed ID: 28857066
[TBL] [Abstract][Full Text] [Related]
19. Continuous rhPTH (1-34) treatment in chronic hypoparathyroidism.
Fuss CT; Burger-Stritt S; Horn S; Koschker AC; Frey K; Meyer A; Hahner S
Endocrinol Diabetes Metab Case Rep; 2020 May; 2020():. PubMed ID: 32478671
[TBL] [Abstract][Full Text] [Related]
20. Effects of parathyroid hormone rhPTH(1-84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study.
Clarke BL; Vokes TJ; Bilezikian JP; Shoback DM; Lagast H; Mannstadt M
Endocrine; 2017 Jan; 55(1):273-282. PubMed ID: 27734257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
